Bildkälla: Stockfoto

Alligator Q3: Progress in the Clinical Programs - Redeye

Redeye discusses events and financial results in Q3 2022. Progress has been made with ATOR-1017, mitazalimab and ALG.APV-527.

Redeye discusses events and financial results in Q3 2022. Progress has been made with ATOR-1017, mitazalimab and ALG.APV-527.
Börsvärldens nyhetsbrev
ANNONSER